Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C

[Business Wire] – Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has granted its investigational DCV Dual Regimen Breakthrough Therapy Designation for use as a combination therapy in the treatment of genotype 1b c more

View todays social media effects on BMY

View the latest stocks trending across Twitter. Click to view dashboard

See who Bristol is hiring next, click here to view